Your browser doesn't support javascript.
loading
Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review.
Wang, Siyuan; Tian, Huairu; Tian, Peilin; Xing, Yiwen; Zeng, Yuan.
Afiliação
  • Wang S; Suzhou Institute for Drug Control, Suzhou, China.
  • Tian H; Suzhou Institute for Drug Control, Suzhou, China.
  • Tian P; Suzhou Institute for Drug Control, Suzhou, China.
  • Xing Y; Suzhou Institute for Drug Control, Suzhou, China.
  • Zeng Y; Clinical Pharmacology and Bioanalytics, Development China, Pfizer Pharmaceutical Ltd., Shanghai, China.
Transl Cancer Res ; 13(2): 1150-1165, 2024 Feb 29.
Article em En | MEDLINE | ID: mdl-38482428
ABSTRACT
Background and

Objective:

The application of immunotherapy, especially in terms of recombinant monoclonal antibodies (mAbs), is a revolution in the pharmaceutical industry field. Glycosylation plays an essential role in the structures and functions of mAbs, which must be carefully monitored and designed throughout their entire lifespan to ensure safety and efficacy. This review aimed to summarize the current status of the glycoengineering of mAbs for providing reference for the pharmaceutical industry. The application of glycoengineering of mAbs in cancer therapy will also be discussed in this article.

Methods:

We searched the PubMed/MEDLINE database to identify studies published between 1970 and 2023 that investigated glycoengineering of recombinant mAbs and its applications. The major findings of these studies were summarized. Key Content and

Findings:

This article reviews the relationship between glycosylation profiles and antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), shelf-life, and other properties of mAbs. Furthermore, the rational design of glycosylation profiles provides solutions to the unmet needs of new drug development and biosimilar manufacturers. This review also emphatically describes various feasible strategies to optimize the glycosylation pattern in biomanufacturing reported in recent years, especially the approaches of combinatory glycoengineering explored in this field. Finally, we share examples of glycoengineering of mAbs applied in cancer therapy.

Conclusions:

Glycan modifications have been achieved through genetic and metabolic glycoengineering. A better understanding of the interplay between cells and the exogenous environment help the combinatorial strategy for glycoengineering in precise control mode. Furthermore, new high-tech approaches for glycoengineering are leading biological engineering and biotherapeutics to a new stage.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article